New MRI method for breast cancer screening
Development and Testing of an Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening - A Pilot Study
This study is testing a new MRI method for breast cancer screening in women with dense breasts or at moderate risk to see if it can find cancers earlier and more accurately than regular mammograms.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 40 Years to 74 Years |
| Sex | Female |
| Sponsor | University of Chicago Academic / other |
| Locations | 1 site (Chicago, Illinois) |
| Trial ID | NCT04877912 on ClinicalTrials.gov |
What this trial studies
This study tests an innovative MRI screening method for breast cancer in women with dense breasts and those at moderately increased risk. The approach combines MRI with risk assessment to enhance cancer detection sensitivity, aiming to identify cancers at earlier stages and reduce the occurrence of interval cancers compared to traditional mammography. Radiologists will interpret MRI images to identify suspicious lesions, which will then be coded for further evaluation or biopsy.
Who should consider this trial
Good fit: Ideal candidates are women aged 40-74 with dense breasts and an average to intermediate risk of breast cancer.
Not a fit: Patients with metallic implants, claustrophobia, or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this method could lead to earlier detection of breast cancer, potentially reducing mortality rates.
How similar studies have performed: Previous studies have shown promising results for MRI in breast cancer screening, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women that have had a mammographically and/or sonographically identified finding that will require image guided biopsy * Women between ages 40-74 with dense breasts having a mammogram * Women identified as having an average or intermediate risk of breast cancer (defined as 10- 20% lifetime risk based on a clinical risk model). Exclusion Criteria: * Women with metallic implants * Women that are claustrophobic * Women that have a fear of needles or contrast * Women that have had an allergic reaction to contrast in the past * Women that are pregnant * Women who are demonstrated to be at risk for an allergic reaction or nephrogenic systemic fibrosis (NSF)
Where this trial is running
Chicago, Illinois
- University of Chicago Mitchell Hospital — Chicago, Illinois, United States (Recruiting)
Study contacts
- Study coordinator: Rabia Safi, MD
- Email: rsafi@radiology.bsd.uchicago.edu
- Phone: 773-702-2777
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.